|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: COPS8 |
Gene summary for COPS8 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | COPS8 | Gene ID | 10920 |
| Gene name | COP9 signalosome subunit 8 | |
| Gene Alias | COP9 | |
| Cytomap | 2q37.3 | |
| Gene Type | protein-coding | GO ID | GO:0000338 | UniProtAcc | A0A024R4D1 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 10920 | COPS8 | LZE4T | Human | Esophagus | ESCC | 1.82e-18 | 3.32e-01 | 0.0811 |
| 10920 | COPS8 | LZE8T | Human | Esophagus | ESCC | 1.96e-07 | 3.96e-01 | 0.067 |
| 10920 | COPS8 | LZE20T | Human | Esophagus | ESCC | 3.25e-03 | 1.39e-01 | 0.0662 |
| 10920 | COPS8 | LZE24T | Human | Esophagus | ESCC | 2.62e-16 | 6.41e-01 | 0.0596 |
| 10920 | COPS8 | LZE21T | Human | Esophagus | ESCC | 3.54e-02 | 2.47e-01 | 0.0655 |
| 10920 | COPS8 | LZE6T | Human | Esophagus | ESCC | 4.45e-09 | 4.96e-01 | 0.0845 |
| 10920 | COPS8 | P1T-E | Human | Esophagus | ESCC | 1.70e-08 | 2.88e-01 | 0.0875 |
| 10920 | COPS8 | P2T-E | Human | Esophagus | ESCC | 8.49e-39 | 5.79e-01 | 0.1177 |
| 10920 | COPS8 | P4T-E | Human | Esophagus | ESCC | 1.83e-23 | 6.93e-01 | 0.1323 |
| 10920 | COPS8 | P5T-E | Human | Esophagus | ESCC | 1.26e-42 | 9.11e-01 | 0.1327 |
| 10920 | COPS8 | P8T-E | Human | Esophagus | ESCC | 4.36e-26 | 5.04e-01 | 0.0889 |
| 10920 | COPS8 | P9T-E | Human | Esophagus | ESCC | 6.84e-19 | 5.86e-01 | 0.1131 |
| 10920 | COPS8 | P10T-E | Human | Esophagus | ESCC | 1.57e-30 | 6.48e-01 | 0.116 |
| 10920 | COPS8 | P11T-E | Human | Esophagus | ESCC | 7.39e-22 | 7.60e-01 | 0.1426 |
| 10920 | COPS8 | P12T-E | Human | Esophagus | ESCC | 4.46e-50 | 8.92e-01 | 0.1122 |
| 10920 | COPS8 | P15T-E | Human | Esophagus | ESCC | 5.63e-44 | 1.10e+00 | 0.1149 |
| 10920 | COPS8 | P16T-E | Human | Esophagus | ESCC | 3.70e-42 | 7.90e-01 | 0.1153 |
| 10920 | COPS8 | P17T-E | Human | Esophagus | ESCC | 4.34e-10 | 6.11e-01 | 0.1278 |
| 10920 | COPS8 | P19T-E | Human | Esophagus | ESCC | 7.78e-07 | 9.08e-01 | 0.1662 |
| 10920 | COPS8 | P20T-E | Human | Esophagus | ESCC | 1.79e-35 | 7.28e-01 | 0.1124 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:004586018 | Esophagus | ESCC | positive regulation of protein kinase activity | 219/8552 | 386/18723 | 6.91e-06 | 6.97e-05 | 219 |
| GO:003367420 | Esophagus | ESCC | positive regulation of kinase activity | 260/8552 | 467/18723 | 7.26e-06 | 7.22e-05 | 260 |
| GO:007064612 | Esophagus | ESCC | protein modification by small protein removal | 95/8552 | 157/18723 | 1.25e-04 | 8.56e-04 | 95 |
| GO:000033812 | Esophagus | ESCC | protein deneddylation | 10/8552 | 10/18723 | 3.94e-04 | 2.26e-03 | 10 |
| GO:00380615 | Esophagus | ESCC | NIK/NF-kappaB signaling | 81/8552 | 143/18723 | 5.33e-03 | 2.00e-02 | 81 |
| GO:0038061 | Liver | Cirrhotic | NIK/NF-kappaB signaling | 54/4634 | 143/18723 | 3.64e-04 | 3.07e-03 | 54 |
| GO:0000338 | Liver | Cirrhotic | protein deneddylation | 7/4634 | 10/18723 | 3.29e-03 | 1.83e-02 | 7 |
| GO:004586011 | Liver | Cirrhotic | positive regulation of protein kinase activity | 117/4634 | 386/18723 | 7.07e-03 | 3.41e-02 | 117 |
| GO:00706461 | Liver | HCC | protein modification by small protein removal | 91/7958 | 157/18723 | 6.50e-05 | 5.92e-04 | 91 |
| GO:004586021 | Liver | HCC | positive regulation of protein kinase activity | 194/7958 | 386/18723 | 1.16e-03 | 6.54e-03 | 194 |
| GO:003367411 | Liver | HCC | positive regulation of kinase activity | 230/7958 | 467/18723 | 1.72e-03 | 8.95e-03 | 230 |
| GO:00003381 | Liver | HCC | protein deneddylation | 9/7958 | 10/18723 | 2.79e-03 | 1.31e-02 | 9 |
| GO:00380611 | Liver | HCC | NIK/NF-kappaB signaling | 77/7958 | 143/18723 | 3.98e-03 | 1.76e-02 | 77 |
| GO:00321471 | Liver | HCC | activation of protein kinase activity | 72/7958 | 134/18723 | 5.61e-03 | 2.33e-02 | 72 |
| GO:004586016 | Oral cavity | OSCC | positive regulation of protein kinase activity | 194/7305 | 386/18723 | 3.90e-06 | 4.59e-05 | 194 |
| GO:003367418 | Oral cavity | OSCC | positive regulation of kinase activity | 228/7305 | 467/18723 | 8.31e-06 | 8.90e-05 | 228 |
| GO:00003382 | Oral cavity | OSCC | protein deneddylation | 10/7305 | 10/18723 | 8.14e-05 | 6.26e-04 | 10 |
| GO:00380614 | Oral cavity | OSCC | NIK/NF-kappaB signaling | 78/7305 | 143/18723 | 1.14e-04 | 8.35e-04 | 78 |
| GO:00706462 | Oral cavity | OSCC | protein modification by small protein removal | 77/7305 | 157/18723 | 6.55e-03 | 2.43e-02 | 77 |
| GO:000033811 | Oral cavity | LP | protein deneddylation | 9/4623 | 10/18723 | 2.64e-05 | 4.21e-04 | 9 |
| Page: 1 2 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| COPS8 | SNV | Missense_Mutation | c.61N>A | p.Glu21Lys | p.E21K | Q99627 | protein_coding | deleterious(0) | possibly_damaging(0.77) | TCGA-AN-A0FJ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
| COPS8 | SNV | Missense_Mutation | c.158C>G | p.Ala53Gly | p.A53G | Q99627 | protein_coding | deleterious(0) | possibly_damaging(0.613) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| COPS8 | SNV | Missense_Mutation | c.349G>T | p.Ala117Ser | p.A117S | Q99627 | protein_coding | deleterious(0.04) | benign(0.026) | TCGA-EK-A2R7-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| COPS8 | insertion | Frame_Shift_Ins | novel | c.591_592insACTTTCTTAGATTT | p.Ala198ThrfsTer8 | p.A198Tfs*8 | Q99627 | protein_coding | TCGA-AM-5820-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| COPS8 | SNV | Missense_Mutation | novel | c.197N>A | p.Ser66Tyr | p.S66Y | Q99627 | protein_coding | deleterious(0) | possibly_damaging(0.766) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| COPS8 | SNV | Missense_Mutation | c.200C>T | p.Ala67Val | p.A67V | Q99627 | protein_coding | tolerated(0.06) | possibly_damaging(0.598) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| COPS8 | SNV | Missense_Mutation | rs760027685 | c.347N>A | p.Arg116His | p.R116H | Q99627 | protein_coding | deleterious(0) | possibly_damaging(0.786) | TCGA-AX-A1CE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | SD |
| COPS8 | SNV | Missense_Mutation | c.283G>A | p.Ala95Thr | p.A95T | Q99627 | protein_coding | deleterious(0.02) | benign(0.058) | TCGA-AX-A2HD-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
| COPS8 | SNV | Missense_Mutation | novel | c.204T>A | p.Asn68Lys | p.N68K | Q99627 | protein_coding | tolerated(0.09) | benign(0.339) | TCGA-B5-A0JU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| COPS8 | SNV | Missense_Mutation | c.329N>T | p.Arg110Ile | p.R110I | Q99627 | protein_coding | deleterious(0.03) | possibly_damaging(0.745) | TCGA-BS-A0UF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |